JP7336434B2 - アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 - Google Patents
アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 Download PDFInfo
- Publication number
- JP7336434B2 JP7336434B2 JP2020505412A JP2020505412A JP7336434B2 JP 7336434 B2 JP7336434 B2 JP 7336434B2 JP 2020505412 A JP2020505412 A JP 2020505412A JP 2020505412 A JP2020505412 A JP 2020505412A JP 7336434 B2 JP7336434 B2 JP 7336434B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- cancer
- compounds
- converted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Epoxy Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17184272.7 | 2017-08-01 | ||
| EP17184272 | 2017-08-01 | ||
| PCT/EP2018/067797 WO2019025099A1 (en) | 2017-08-01 | 2018-07-02 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020528922A JP2020528922A (ja) | 2020-10-01 |
| JPWO2019025099A5 JPWO2019025099A5 (https=) | 2022-10-04 |
| JP2020528922A5 JP2020528922A5 (https=) | 2022-10-04 |
| JP7336434B2 true JP7336434B2 (ja) | 2023-08-31 |
Family
ID=59506176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505412A Active JP7336434B2 (ja) | 2017-08-01 | 2018-07-02 | アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11186592B2 (https=) |
| EP (1) | EP3661941B1 (https=) |
| JP (1) | JP7336434B2 (https=) |
| KR (1) | KR102717280B1 (https=) |
| CN (1) | CN110997681B (https=) |
| AU (1) | AU2018309265B2 (https=) |
| CA (1) | CA3071575A1 (https=) |
| DK (1) | DK3661941T3 (https=) |
| ES (1) | ES2940407T3 (https=) |
| FI (1) | FI3661941T3 (https=) |
| HR (1) | HRP20230251T1 (https=) |
| HU (1) | HUE061308T2 (https=) |
| IL (1) | IL272284B2 (https=) |
| LT (1) | LT3661941T (https=) |
| NZ (1) | NZ760516A (https=) |
| PL (1) | PL3661941T3 (https=) |
| PT (1) | PT3661941T (https=) |
| RS (1) | RS64035B1 (https=) |
| SG (1) | SG11202000823WA (https=) |
| SI (1) | SI3661941T1 (https=) |
| TW (1) | TWI850199B (https=) |
| WO (1) | WO2019025099A1 (https=) |
| ZA (1) | ZA202001295B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022524914A (ja) * | 2019-01-22 | 2022-05-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112174943A (zh) * | 2019-07-03 | 2021-01-05 | 四川大学 | 一种吲哚-2-酮类化合物在制备防治口腔细菌产品中的用途 |
| WO2022258622A1 (en) | 2021-06-07 | 2022-12-15 | Ares Trading S.A. | Combination treatment of cancer |
| KR20250048043A (ko) | 2022-08-02 | 2025-04-07 | 메르크 파텐트 게엠베하 | (S)-7-옥사-2-아자-스피로[4.5]데칸-2-카르복실산 [7-(3,6-디히드로-2H-피란-4-일)-4-메톡시-티아졸로[4,5-c]피리딘-2-일]-아미드의 신규의 결정질 형태 및 이의 공-결정 형태 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006528220A (ja) | 2003-05-19 | 2006-12-14 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体リガンドとしてのベンゾチアゾール誘導体 |
| JP2007505851A (ja) | 2003-09-19 | 2007-03-15 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体リガンドとしてのチアゾピリジン誘導体 |
| WO2016046530A1 (en) | 2014-09-23 | 2016-03-31 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4207554A (en) | 1972-08-04 | 1980-06-10 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| US4125828A (en) | 1972-08-04 | 1978-11-14 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| AU1688599A (en) | 1998-01-05 | 1999-07-26 | Eisai Co. Ltd. | Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| US6841549B1 (en) | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| AU8181701A (en) * | 2000-06-21 | 2002-01-02 | Hoffmann La Roche | Benzothiazole derivatives |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| US6713499B2 (en) * | 2001-12-12 | 2004-03-30 | Hoffman-La Roche Inc. | 7-Amino-benzothiazole derivatives |
| EP1465634B1 (en) | 2001-12-12 | 2014-10-22 | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services | Methods for using adenosine receptor inhibitors to enhance immune response and inflammation |
| EP1618108A2 (en) | 2003-04-09 | 2006-01-25 | Biogen Idec MA Inc. | Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists |
| US6872833B2 (en) * | 2003-04-14 | 2005-03-29 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| CN1989139B (zh) | 2004-07-22 | 2010-05-12 | 弗·哈夫曼-拉罗切有限公司 | 苯并噻唑衍生物 |
| JP5026511B2 (ja) * | 2006-05-18 | 2012-09-12 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシンａ２ｂレセプターアンタゴニストとしてのチアゾロ−ピラミジン／ピリジン尿素誘導体 |
| US8168785B2 (en) * | 2009-06-17 | 2012-05-01 | Biotie Therapies, Inc. | Benzothiazole derivatives |
-
2018
- 2018-07-02 RS RS20230195A patent/RS64035B1/sr unknown
- 2018-07-02 FI FIEP18733649.0T patent/FI3661941T3/fi active
- 2018-07-02 LT LTEPPCT/EP2018/067797T patent/LT3661941T/lt unknown
- 2018-07-02 AU AU2018309265A patent/AU2018309265B2/en active Active
- 2018-07-02 CN CN201880050465.4A patent/CN110997681B/zh active Active
- 2018-07-02 SI SI201830863T patent/SI3661941T1/sl unknown
- 2018-07-02 JP JP2020505412A patent/JP7336434B2/ja active Active
- 2018-07-02 SG SG11202000823WA patent/SG11202000823WA/en unknown
- 2018-07-02 HR HRP20230251TT patent/HRP20230251T1/hr unknown
- 2018-07-02 PT PT187336490T patent/PT3661941T/pt unknown
- 2018-07-02 PL PL18733649.0T patent/PL3661941T3/pl unknown
- 2018-07-02 KR KR1020207006084A patent/KR102717280B1/ko active Active
- 2018-07-02 CA CA3071575A patent/CA3071575A1/en active Pending
- 2018-07-02 HU HUE18733649A patent/HUE061308T2/hu unknown
- 2018-07-02 IL IL272284A patent/IL272284B2/en unknown
- 2018-07-02 US US16/635,356 patent/US11186592B2/en active Active
- 2018-07-02 ES ES18733649T patent/ES2940407T3/es active Active
- 2018-07-02 NZ NZ760516A patent/NZ760516A/en unknown
- 2018-07-02 WO PCT/EP2018/067797 patent/WO2019025099A1/en not_active Ceased
- 2018-07-02 DK DK18733649.0T patent/DK3661941T3/da active
- 2018-07-02 EP EP18733649.0A patent/EP3661941B1/en active Active
- 2018-07-31 TW TW107126410A patent/TWI850199B/zh active
-
2020
- 2020-02-28 ZA ZA2020/01295A patent/ZA202001295B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006528220A (ja) | 2003-05-19 | 2006-12-14 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体リガンドとしてのベンゾチアゾール誘導体 |
| JP2007505851A (ja) | 2003-09-19 | 2007-03-15 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体リガンドとしてのチアゾピリジン誘導体 |
| WO2016046530A1 (en) | 2014-09-23 | 2016-03-31 | Mission Therapeutics Ltd | Novel compounds |
Non-Patent Citations (1)
| Title |
|---|
| Journal of Medicinal Chemistry，2017年，Vol. 60，pp. 681-694 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022524914A (ja) * | 2019-01-22 | 2022-05-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 |
| JP7600119B2 (ja) | 2019-01-22 | 2024-12-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7287952B2 (ja) | アデノシン受容体アンタゴニストとしてのベンズイミダゾール誘導体 | |
| JP7287951B2 (ja) | アデノシン受容体アンタゴニストとしてのキノキサリン誘導体 | |
| ES2660914T3 (es) | Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD | |
| KR20220068243A (ko) | 포스포디에스테라제 억제제 및 용도 | |
| KR102891741B1 (ko) | 아데노신 수용체 길항제로서의 티아졸로피리딘 유도체 | |
| JP7336434B2 (ja) | アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 | |
| WO2014151630A2 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| US20250049814A1 (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
| RU2790011C2 (ru) | Тиазолопиридиновые производные в качестве антагонистов аденозиновых рецепторов | |
| RU2781429C2 (ru) | Бензимидазольные производные в качестве антагонистов аденозиновых рецепторов | |
| RU2791168C1 (ru) | Хиноксалиновые производные в качестве антагонистов аденозиновых рецепторов | |
| RU2810114C2 (ru) | Тиазолопиридиновые производные в качестве антагонистов аденозиновых рецепторов | |
| BR112020001978B1 (pt) | Derivados de tiazolopiridina como antagonistas de receptor de adenosina, seu processo de preparação e seu uso, preparação farmacêutica e seu processo de preparação, e kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210701 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220922 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20220922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230425 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230720 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230821 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7336434 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |